Non-small cell lung cancer treatment ‘Tagrisso’ applied for health insurance benefits from 5 December
The health insurance benefits of ‘Tagrisso,’ a non-small cell lung cancer treatment completed with the drug price negotiation, was decided registration and will be applied from 5 December.
Compensation plans for the insurance benefit increase on underrated products were also discussed.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.